AbbVie v. Hetero USA: 34-Patent RINVOQ Infringement Action Dismissed Without Prejudice
AbbVie filed against Hetero USA and nine additional generic challengers in Delaware, asserting 34 patents covering its blockbuster JAK inhibitor RINVOQ (upadacitinib) across 15 mg, 30 mg, and 45 mg extended release tablet doses. After 662 days of litigation before Judge Maryellen Noreika, the court dismissed all allegations without prejudice — leaving the door open to refiling.
AbbVie’s 34-patent RINVOQ fortress meets its first procedural exit
AbbVie, Inc. filed this Hatch-Waxman infringement action in the District of Delaware on 20 November 2023, targeting Hetero USA, Inc. as lead defendant alongside nine further generics — including Sandoz entities, Intas Pharmaceuticals, Accord Healthcare, Sun Pharmaceutical, Aurobindo Pharma, and Hetero Labs. The complaint asserted an unusually large portfolio of 34 US patents covering upadacitinib, the active ingredient in RINVOQ extended release tablets approved at 15 mg, 30 mg, and 45 mg strengths for inflammatory conditions.
The case closed on 12 September 2025 after 662 days, with Judge Maryellen Noreika ordering dismissal without prejudice. A without-prejudice dismissal means no judgment was entered on the merits; AbbVie retains the right to refile these or related claims, and no defendant obtained a declaratory judgment of non-infringement or invalidity. The public record does not disclose whether the dismissal followed a settlement, a voluntary withdrawal by AbbVie, or a procedural development — the basis of termination is recorded only as ‘Dismissed without Prejudice.’
The 662-day duration suggests the parties engaged substantively before resolution, yet the absence of a merits ruling leaves the competitive landscape uncertain for all generic entrants. The large defendant roster — ten companies across multiple corporate families — is consistent with parallel ANDA filings and is a hallmark of high-value Paragraph IV litigation. What drove the withdrawal, and whether any defendant reached a confidential settlement permitting future market entry, remains unknown from the public record.
Filing to Dismissed without Prejudice in 662 days
662 days — above average for a Hatch-Waxman ANDA case to resolve without a merits ruling
Dismissed without prejudice: what this ruling means for AbbVie and the generic defendants
Without prejudice means no merits decision — and no finality
A dismissal without prejudice under federal civil procedure extinguishes the current action but does not bar AbbVie from filing a new complaint asserting the same or related patents against the same defendants. No court has ruled on infringement, validity, or enforceability of any of the 34 patents. This is a procedural exit, not a substantive win for either side.
No merits adjudicationAbbVie preserves all claims — and all leverage
Because the dismissal is without prejudice, AbbVie’s 34-patent portfolio emerges intact. None of the asserted patents has been found invalid or not infringed. AbbVie can refile against any defendant whose ANDA remains pending or whose product remains unlaunched. The dismissal may also reflect a confidential settlement providing AbbVie with agreed-upon entry dates — the public record is silent on this point.
Portfolio rights preservedGenerics gain no patent clearance from this dismissal
None of the ten generic defendants obtained a finding of non-infringement or invalidity. They cannot point to this dismissal as patent clearance. Any defendant who did not settle faces the prospect of renewed litigation before FDA approval is acted upon. Those who may have settled likely received a negotiated launch date — but this is not confirmed by the public record.
No invalidity finding obtainedRINVOQ’s patent fortress remains standing for now
With no merits ruling, AbbVie’s 34-patent estate around upadacitinib continues to deter at-risk generic entry. RINVOQ generated multi-billion dollar annual revenues globally, making this portfolio commercially critical. Generic entrants in the JAK inhibitor space should treat all 34 asserted patents as live enforcement risks until expiry or a future invalidity ruling in IPR or subsequent litigation.
High refiling risk for genericsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | AbbVie, Inc. | Company | Global biopharmaceutical company — holder of US9879018B2 and 33 further upadacitinib patentsSearch in Eureka ↗ |
| Defendant | Hetero USA, Inc. | Company | Generic pharmaceutical manufacturers and their affiliates seeking ANDA approval for upadacitinib ER tabletsSearch in Eureka ↗ |
| Co-Defendant | Sandoz Private Limited | Individual | Search in Eureka ↗ |
| Co-Defendant | Intas Pharmaceuticals, Ltd. | Company | Search in Eureka ↗ |
| Co-Defendant | Hetero Labs Limited | Individual | Search in Eureka ↗ |
| Co-Defendant | Accord Healthcare, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Sun Pharmaceutical Industries, Ltd. | Company | Search in Eureka ↗ |
| Co-Defendant | Sandoz, GmbH | Company | Search in Eureka ↗ |
| Co-Defendant | Hetero Labs Limited | Individual | Search in Eureka ↗ |
| Co-Defendant | Aurobindo Pharma, Ltd. | Company | Search in Eureka ↗ |
| Co-Defendant | Aurobindo Pharma USA, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Sandoz, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Brianne Bharkhda | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Christopher N. Sipes | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Erica N. Andersen | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jeremy A. Tigan | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Laura M. Martin | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Megan Elizabeth Dellinger | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Megan L. Hare | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Nicholas L. Evoy | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing AbbVie, Inc.Search in Eureka ↗ |
| Defendant counsel | Anne M. Rock | Attorney | Counsel for Hetero USA, Inc.Search in Eureka ↗ |
| Defendant counsel | Benjamin J. Schladweiler | Attorney | Counsel for Hetero USA, Inc.Search in Eureka ↗ |
| Defendant counsel | Brian J. Prew | Attorney | Counsel for Hetero USA, Inc.Search in Eureka ↗ |
| Defendant counsel | Giancarlo Scaccia | Attorney | Counsel for Hetero USA, Inc.Search in Eureka ↗ |
| Defendant counsel | Jonathan R. Wise | Attorney | Counsel for Hetero USA, Inc.Search in Eureka ↗ |
| Defendant counsel | Kathryn E. Albanese | Attorney | Counsel for Hetero USA, Inc.Search in Eureka ↗ |
| Defendant counsel | Renee Mosley Delcollo | Attorney | Counsel for Hetero USA, Inc.Search in Eureka ↗ |
| Defendant law firm | Greenberg Traurig PA | Law Firm | Representing Hetero USA, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Maryellen Noreika | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The verdict language — ‘allegations and averments contained therein, should be dismissed, without prejudice’ — is a procedural termination formula, not a substantive ruling. It confirms that no court has assessed the merits of AbbVie’s infringement claims or the defendants’ validity defences across any of the 34 patents. For the defendants, this provides no patent clearance; for AbbVie, all enforcement rights are preserved. The phrasing is consistent with either a voluntary stipulation agreed by the parties or a court-ordered procedural termination, but the public record does not specify which.
US9879018B2 — upadacitinib compound and formulation patents (RINVOQ)
The 34 asserted patents span the full lifecycle of upadacitinib — from early compound claims (US9879018B2, US8962629B2) through crystalline forms, synthesis processes, extended release formulation technology, and treatment methods. US9879018B2, filed on application US15/682451, covers core upadacitinib compound claims. The portfolio also includes a reissue patent (USRE47221E), which typically signals AbbVie broadened or corrected claims post-grant, and multiple continuation patents filed as recently as 2023, extending potential exclusivity well into the 2030s.
RINVOQ (upadacitinib) is a selective JAK1 inhibitor approved for rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and Crohn’s disease — a multi-indication blockbuster generating over $4 billion annually. A portfolio of 34 patents covering compound, formulation, and method-of-use claims creates a dense exclusivity web that any generic entrant must navigate via Paragraph IV certification. The breadth and recency of the continuation filings suggest AbbVie has strategically extended protection well beyond the original compound patent, raising the cost and complexity of generic entry.
Should you run an FTO analysis against AbbVie’s upadacitinib patent estate?
Any company developing a generic or biosimilar upadacitinib product, or a novel JAK1 inhibitor with structural or formulation overlap, should treat AbbVie’s 34-patent estate as a live freedom-to-operate concern. The without-prejudice dismissal here provides no clearance. Formulation scientists developing extended release JAK inhibitor tablets, process chemists working on upadacitinib synthesis routes, and commercial teams evaluating ANDA filing strategy all face direct exposure until individual patents expire or are invalidated.
PatSnap Eureka’s FTO Search Agent can map each of the 34 asserted patents against your specific product configuration — identifying claim overlap, prosecution history estoppel, and expiry timelines across compound, formulation, and method-of-use claims. Eureka’s AI-assisted claim charting accelerates the analysis from weeks to hours, helping your IP and R&D teams make data-driven go/no-go decisions before committing to an ANDA or NDA filing.
Run a freedom-to-operate analysis on US9879018B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman JAK inhibitor patent cases in Delaware
Browse related Paragraph IV infringement actions asserting JAK inhibitor and small-molecule inflammatory disease patents before the Delaware District Court.
What this case signals for the JAK inhibitor generic IP landscape
A 34-patent Hatch-Waxman case dismissed without prejudice rarely signals a clean victory for either side — the strategic picture is nuanced.
34-patent ANDA cases signal evergreening risk — track each patent’s expiry
AbbVie’s deployment of 34 patents in a single ANDA case is consistent with a layered evergreening strategy. Generic challengers and IP teams should map each patent’s independent expiry and claim scope. A single surviving patent can block market entry even if 33 others are invalidated or expired.
Without-prejudice dismissals in Hatch-Waxman cases often mask settlements
In Paragraph IV litigation, without-prejudice dismissals frequently accompany confidential settlement agreements that include negotiated launch dates. Monitoring subsequent Orange Book patent delistings or 30-month stay expirations for upadacitinib can signal whether a settlement has closed the commercial risk window for any specific defendant.
AbbVie v Hetero — key questions answered
A without-prejudice dismissal means no court ruled on infringement or validity of AbbVie’s 34 upadacitinib patents. Generic defendants obtained no patent clearance. AbbVie retains the right to refile, and the commercial exclusivity of RINVOQ is not legally affected by this dismissal. Generic entry risk remains until individual patents expire or are separately invalidated.
AbbVie asserted 34 US patents in case No. 1:23-cv-01332, covering upadacitinib compound, crystalline forms, synthesis processes, extended release formulations, and methods of treatment. The portfolio includes a reissue patent (USRE47221E) and multiple continuation patents filed through 2023, spanning application dates from 2009 to 2023.
The defendants were Hetero USA, Inc., Hetero Labs Limited (listed twice), Sandoz Private Limited, Sandoz GmbH, Sandoz Inc., Intas Pharmaceuticals Ltd., Accord Healthcare Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., and Aurobindo Pharma USA Inc. — ten entities across multiple generic pharmaceutical corporate families.
Yes. Because the dismissal was without prejudice, AbbVie is not barred from refiling the same infringement claims against any of the defendants. The 30-month Hatch-Waxman stay mechanics and any applicable statutes of limitations would govern the timing of any refiling. The public record does not disclose whether a settlement with any defendant limits AbbVie’s ability to refile against that specific party.
USRE47221E is a reissue patent, which means the USPTO granted AbbVie corrected or broadened claims after the original patent issued. Reissue patents can extend or clarify the scope of protection relative to the original grant and are subject to intervening rights defences if claim scope was broadened. Its inclusion among the 34 asserted patents suggests AbbVie pursued strategic claim refinement for upadacitinib protection.
PatSnap Eureka searches patents and litigation data to answer instantly.